SeekingAlpha · Sep 22, 2026
BrainsWay: Execution Isn't The Problem, Market Size Is
BrainsWay Ltd. is a Hold due to concerns over long-term market size, competition, and potential scale despite execution strength. Read more on BWAY stock here.
NASDAQ · BWAY
BrainsWay Ltd.
Healthcare · Medical - Devices
$11.47
Up+$0.30 (+2.62%)
Updated Oct 10, 2026, 1:32 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 345.63M
- P/E ratio
- 66.66
- Dividend yield
- 0.00%
- 52-week range
- $7.14 – $17.40
- Volume
- 119.71K
- Avg. volume
- 67.63K
Price performance · BWAY
BWAY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
BWAY closed at $11.47 after 20 trading sessions, down 17.66% for the selected period.
- Last close
- $11.47
- Period change
- -17.66%
- Period low
- $11.47
- Period high
- $13.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $11.59 | $11.6099 | $11.37 | $11.47 | 119.71K |
| Oct 7, 2026 | $11.60 | $11.77 | $11.45 | $11.62 | 132.36K |
| Oct 6, 2026 | $12.23 | $12.30 | $11.74 | $11.89 | 143.63K |
| Oct 5, 2026 | $12.29 | $12.34 | $11.93 | $12.23 | 231.2K |
| Oct 2, 2026 | $12.75 | $12.96 | $12.41 | $12.50 | 50.83K |
| Oct 1, 2026 | $12.91 | $12.99 | $12.50 | $12.60 | 138K |
| Sep 30, 2026 | $13.56 | $13.84 | $13.17 | $13.20 | 70.72K |
| Sep 29, 2026 | $13.36 | $13.9943 | $13.1601 | $13.48 | 113.4K |
| Sep 28, 2026 | $13.10 | $13.44 | $12.99 | $13.25 | 179.07K |
| Sep 25, 2026 | $13.21 | $14.38 | $13.07 | $13.31 | 54.53K |
| Sep 24, 2026 | $13.25 | $13.30 | $13.06 | $13.21 | 65.8K |
| Sep 23, 2026 | $13.83 | $14.115 | $13.44 | $13.45 | 90.43K |
| Sep 22, 2026 | $13.14 | $13.72 | $13.024 | $13.63 | 190.93K |
| Sep 21, 2026 | $13.61 | $13.70 | $13.38 | $13.57 | 59.64K |
| Sep 18, 2026 | $13.61 | $13.625 | $13.14 | $13.61 | 47.2K |
| Sep 17, 2026 | $13.425 | $13.70 | $13.15 | $13.53 | 32.57K |
| Sep 16, 2026 | $13.41 | $13.63 | $13.27 | $13.46 | 88.88K |
| Sep 15, 2026 | $13.50 | $13.50 | $13.13 | $13.46 | 123.25K |
| Sep 14, 2026 | $13.51 | $13.835 | $13.3007 | $13.63 | 113.15K |
| Sep 11, 2026 | $14.10 | $14.115 | $13.68 | $13.93 | 68.03K |
Latest BWAY news
The latest Smart Investors Daily articles mentioning BWAY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BWAY research
Overview
Company profile and research snapshot.
Company profile
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $24.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2020 | Raymond James | Outperform | — |
| Mar 24, 2020 | Cantor Fitzgerald | Overweight | — |
| Mar 24, 2020 | Raymond James | Outperform | — |
| Nov 26, 2019 | Raymond James | Outperform | — |
| May 13, 2019 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore
On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]
Benzinga · Sep 10, 2026
BTIG Reiterates Buy on BrainsWay, Maintains $20 Price Target
BTIG analyst Sam Eiber reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $20 price target.
Yahoo · Sep 9, 2026
Are Options Traders Betting on a Big Move in Brainsway Stock?
Investors need to pay close attention to BWAY stock based on the movements in the options market lately.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
